RECOMBIVAX HB™

BIOLOGICAL3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Bacterial Infections; Virus DiseasesPneumococcal InfectionsPneumococcal Vaccines

Phase 2

A Study of the Safety and Tolerability of V419 in Healthy Infants at 2,4, 6 and 12 to 14 Months of Age (V419-003)

CompletedNCT00551915

Merck Sharp & Dohme LLCBacterial Infections; Virus Diseases

Start: 2001-05-31End: 2003-01-31Updated: 2015-10-30

Phase 3

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

CompletedNCT03620162

Merck Sharp & Dohme LLCPneumococcal Infections

Start: 2018-10-18End: 2020-12-14Updated: 2023-01-17

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

CompletedNCT03893448

Merck Sharp & Dohme LLCPneumococcal Infections, Pneumococcal Vaccines

Start: 2019-06-19End: 2021-05-24Updated: 2023-07-28

Related Papers

An indirect treatment comparison (ITC) and matching-adjusted indirect comparison (MAIC) between a 15-valent (V114) and a 20-valent (PCV20) pneumococcal conjugate vaccine among healthy infants

Expert Review of Vaccines2023-10-176 citations

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of a 4-dose regimen of V114, a 15-valent pneumococcal conjugate vaccine, in healthy infants (PNEU-PED)

Vaccine2023-01-0141 citations

A phase 3, multicenter, randomized, double-blind study to evaluate the interchangeability of V114, a 15-valent pneumococcal conjugate vaccine, and PCV13 with respect to safety, tolerability, and immunogenicity in healthy infants (PNEU-DIRECTION).

2022-12-1312 citations